CompletedNot Applicable

ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE

Japan1,134 participantsStarted 2016-07-01

Plain-language summary

The primary objectives of this study is to estimate the real-world safety profile of Eliquis in Japanese Venous Thromboembolism patients and to estimate the risk factors likely to affect the incidence of bleeding. Lastly, the secondary objective of this study is to estimate the real-world effectiveness profile of Eliquis in Japanese Venous Thromboembolism patients.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who are initiating Eliquis for the treatment of VTE or prevention of recurrent VTE for the first time Exclusion Criteria: * Prior treatment with Eliquis for nonvalvular atrial fibrillation or VTE * Patients initiating Eliquis for the treatment of atrial fibrillation * Off-label use of Eliquis Other protocol defined inclusion/exclusion criteria could apply

What they're measuring

The incidence of all treatment-related adverse events ( AE)

Timeframe: 52 Weeks

The incidence of serious adverse events (SAE)

Timeframe: 52 Weeks

The incidence of unexpected treatment-related adverse events

Timeframe: 52 Weeks

The incidence of bleeding

Timeframe: 52 Weeks

Trial details

NCT IDNCT02836457

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2018-07-31

View on ClinicalTrials.gov More Venous Thromboembolism trials